Search results
Results from the WOW.Com Content Network
William Bradley Coley (January 12, 1862 – April 16, 1936) was an American bone surgeon and cancer researcher best known for his early contributions to the study of cancer immunotherapy, specifically causing infection as a way to fight cancer, a practice used as far back as 1550 BC. [1]
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
The Breakthrough is written for the lay reader and includes sections on immunology that have been written for a general audience. It examines the development of cancer immunotherapy, starting with William Coley's work with toxins in the 1890s, moving on to the long hiatus of immunotherapy, and concluding with victory for the believers in the form of regulatory approval of CTLA-4, PD-1, and PD ...
Cellular adoptive immunotherapy is a type of immunotherapy. Immune cells such as T-cells are usually isolated from patients for expansion or engineering purposes and reinfused back into patients to fight diseases using their own immune system .
Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) .
ABC News did not receive a response from Speaker Mike Johnson on whether he'd consider bringing the legislation to the floor for a vote during the final week of the session.
It was too early to say whether ipilimumab made any difference. [59] In 2016, a phase II study using ipilimumab and nivolumab in AR-V7-expressing metastatic castration-resistant prostate cancer was opened. [60] [61] AR-V7 is an androgen receptor splice variant that can be detected in circulating tumor cells of metastatic prostate cancer ...